English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Methods HIV-infected patients on an ATV-containing cART regimen since >2 weeks, with an available ATV concentration obtained by a validated HPLC-UV (group i) 12 ± 2 hours (C12 h) and (group ii) 24 ± 2 hours (C24 h) after drug intake and 24 weeks subsequent virological follow-up, were retrospectively selected. Patients with genotypic resistance to ATV were excluded. Virological failure was defined as HIV-RNA >50 copies/ml after 24 weeks.

Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia